-+ 0.00%
-+ 0.00%
-+ 0.00%

EXCLUSIVE: NewcelX Expects Expanded Strategic Development Collaborations For Diabetes Drug In 2026

Benzinga·04/30/2026 12:00:05
Listen to the news

Outlook for 2026
The Company expects 2026 to be a year of accelerated execution, including:
 Advancing NCEL-101 toward key IND-enabling milestones
 Expanding strategic development collaborations
 Pursuing additional financing and partnership opportunities
 Accelerating development activities following establishment of an integrated post-
merger operating platform